DermTech Inc Share News

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, D...

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses. The Company has continued to rigorously evaluate its growth opportunities and ...

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test (DMT) across all skin types in the real-world clinical setting. The peer-reviewed s...

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that it will discontinue the optional TERT promoter mutation add-on assay for its DermTech Melanoma Test (DMT) effective March 1, 2024. Multiple studies, including the Company's recently completed Trust 2 Study...

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from its Trust 2 Study, which evaluated the foundational gene expression assay component of the DermTech Melanoma Test (DMT) in a real-world clinical setting. “The Trust 2 Study results ...

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DermTech, Inc. (NASDAQ: DMTK) on behalf of long-term stockholders following a class action complaint that was filed against DermTech on October 15, 2023 with a Class Period from May 3, 2022 to November 3, 2022. Our investigation concern...

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022 and November 3, 2022, both dates inclusive (the “Class Period”), of the important December 15, 2023 lead plaintiff deadline. SO WHAT: If you purchased DermTech securities during the Class Period you may be entitled to compensati...

LOS ANGELES, CA / ACCESSWIRE / December 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or "the Company") (NASDAQ:DMTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Invest...